Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer... Show more
EXEL saw its Momentum Indicator move below the 0 level on March 12, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 82 similar instances where the indicator turned negative. In of the 82 cases, the stock moved further down in the following days. The odds of a decline are at .
The 10-day RSI Indicator for EXEL moved out of overbought territory on March 11, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Moving Average Convergence Divergence Histogram (MACD) for EXEL turned negative on March 12, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EXEL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
EXEL broke above its upper Bollinger Band on February 21, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
EXEL moved above its 50-day moving average on February 19, 2025 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for EXEL crossed bullishly above the 50-day moving average on February 21, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EXEL advanced for three days, in of 304 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 293 cases where EXEL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EXEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.570) is normal, around the industry mean (11.636). P/E Ratio (20.824) is within average values for comparable stocks, (63.806). Projected Growth (PEG Ratio) (2.618) is also within normal values, averaging (1.805). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (5.005) is also within normal values, averaging (239.727).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
a developer of small molecule therapies for the treatment of cancer
Industry Biotechnology
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
DJIA | 22.03 | 0.43 | +1.99% |
Global X Dow 30 Covered Call ETF | |||
SPC | 20.99 | 0.10 | +0.48% |
CrossingBridge Pre-Merger SPAC ETF | |||
JPST | 50.52 | -0.01 | -0.02% |
JPMorgan Ultra-Short Income ETF | |||
IGEB | 44.66 | -0.03 | -0.07% |
iShares Investment Grade Systmtc Bd ETF | |||
UUP | 28.39 | -0.03 | -0.11% |
Invesco DB US Dollar Bullish |
A.I.dvisor indicates that over the last year, EXEL has been loosely correlated with SRPT. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if EXEL jumps, then SRPT could also see price increases.
Ticker / NAME | Correlation To EXEL | 1D Price Change % | ||
---|---|---|---|---|
EXEL | 100% | -0.41% | ||
SRPT - EXEL | 36% Loosely correlated | -1.20% | ||
ALNY - EXEL | 34% Loosely correlated | +0.00% | ||
TECH - EXEL | 33% Poorly correlated | +3.81% | ||
MRSN - EXEL | 32% Poorly correlated | +3.75% | ||
ORMP - EXEL | 32% Poorly correlated | N/A | ||
More |
Ticker / NAME | Correlation To EXEL | 1D Price Change % |
---|---|---|
EXEL | 100% | -0.41% |
modules theme (9 stocks) | 26% Poorly correlated | +2.34% |
treatment theme (53 stocks) | 21% Poorly correlated | +0.45% |
cancer theme (81 stocks) | 20% Poorly correlated | +0.83% |
drugs theme (248 stocks) | 18% Poorly correlated | +2.08% |
biotechnology theme (234 stocks) | 18% Poorly correlated | +2.01% |